News | December 05, 2021
Eris signs JV with MJ Biopharm to supply insulin in India
MJ will be paid a one-time lumpsum licence fee of Rs 15 crore
MJ will be paid a one-time lumpsum licence fee of Rs 15 crore
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
Oravax's vaccine technology is highly scalable for manufacturing and is easily transferable for wide scale logistical distribution, as there is no need for freezer storage
This agreement marks a milestone for Baidu to use its strengths in computational biology to optimize mRNA vaccine and therapy designs
GreenLight Biosciences is a Boston-based biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
Vakrangee’s distribution network across rural India will help penetrate underserved markets
The consideration for the acquisition is US $ 2.25 million
The company has operations in North America, Asia, and Europe,
Subscribe To Our Newsletter & Stay Updated
